{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rectal+Melanoma&page=7",
    "query": {
      "condition": "Rectal Melanoma",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 223,
    "total_pages": 23,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rectal+Melanoma&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rectal+Melanoma&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T12:32:33.904Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00096083",
      "title": "Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "isolated perfusion",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Delcath Systems Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2004-09",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2013-10-23",
      "last_synced_at": "2026-10-11T12:32:33.904Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096083"
    },
    {
      "nct_id": "NCT03452774",
      "title": "SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer, Metastatic",
        "Cancer",
        "Cancer of Pancreas",
        "Cancer of Liver",
        "Cancer of Stomach",
        "Cancer Liver",
        "Cancer of Rectum",
        "Cancer of Kidney",
        "Cancer of Esophagus",
        "Cancer of Cervix",
        "Cancer of Colon",
        "Cancer of Larynx",
        "Cancer, Lung",
        "Cancer, Breast",
        "Cancer, Advanced",
        "Cancer Prostate",
        "Cancer of Neck",
        "Cancer of Skin",
        "Neuroendocrine Tumors",
        "Carcinoma",
        "Mismatch Repair Deficiency",
        "BRCA Gene Rearrangement",
        "Non Hodgkin Lymphoma",
        "Leukemia",
        "Non Small Cell Lung Cancer",
        "Cholangiocarcinoma",
        "Glioblastoma",
        "Central Nervous System Tumor",
        "Melanoma",
        "Urothelial Carcinoma",
        "Bladder Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Testicular Cancer",
        "Breast Cancer",
        "COVID",
        "Myelofibrosis",
        "Myeloproliferative Neoplasm",
        "Myeloproliferative Disorders",
        "Follicular Lymphoma",
        "Mantle Cell Lymphoma",
        "Marginal Zone Lymphoma",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Clinical Trial Matching",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Massive Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 50000,
      "start_date": "2018-01-01",
      "completion_date": "2040-06",
      "has_results": false,
      "last_update_posted_date": "2025-10-28",
      "last_synced_at": "2026-10-11T12:32:33.904Z",
      "location_count": 67,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 64 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03452774"
    },
    {
      "nct_id": "NCT00378482",
      "title": "A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Neoplasms",
        "Melanoma",
        "Prostatic Neoplasms",
        "Renal Cell Carcinoma",
        "Neoplasms",
        "Patients Who Have/Have Had Melanoma and Other Tumors"
      ],
      "interventions": [
        {
          "name": "CP-675,206 (Tremelimumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 37,
      "start_date": "2007-03-05",
      "completion_date": "2023-10-27",
      "has_results": true,
      "last_update_posted_date": "2024-08-22",
      "last_synced_at": "2026-10-11T12:32:33.904Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00378482"
    },
    {
      "nct_id": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Astrocytoma, IDH-Mutant",
        "Glioblastoma, IDH-wildtype",
        "Brain Metastases, Adult",
        "Cervical Cancer",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Esophageal Squamous Cell Carcinoma",
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Melanoma",
        "Merkel Cell Carcinoma",
        "Microsatellite Instability-High Solid Malignant Tumor",
        "Mismatch Repair Deficient Solid Malignant Tumor",
        "Microsatellite Instability-High Colorectal Cancer",
        "Mismatch Repair Deficient Colorectal Cancer",
        "Non-small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Small Cell Lung Cancer",
        "Squamous Cell Carcinoma",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "NEO212 Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Regorafenib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI Protocol",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neonc Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2023-11-01",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-11T12:32:33.904Z",
      "location_count": 8,
      "location_summary": "Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06047379"
    },
    {
      "nct_id": "NCT04593277",
      "title": "Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Clinical Stage I Cutaneous Melanoma AJCC v8",
        "Clinical Stage II Cutaneous Melanoma AJCC v8",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Invasive Malignant Neoplasm",
        "Leukemia",
        "Lymphoma",
        "Malignant Solid Neoplasm",
        "Sarcoma",
        "Stage I Colorectal Cancer AJCC v8",
        "Stage II Colorectal Cancer AJCC v8",
        "Stage III Colorectal Cancer AJCC v8",
        "Anatomic Stage I Breast Cancer AJCC v8",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Internet Mobile Technology",
          "type": "OTHER"
        },
        {
          "name": "Internet-Based Intervention",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care",
          "type": "PROCEDURE"
        },
        {
          "name": "Informational Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 549,
      "start_date": "2022-10-23",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-10-11T12:32:33.904Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04593277"
    },
    {
      "nct_id": "NCT00375245",
      "title": "Rapamycin With Grapefruit Juice for Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumors",
        "Neoplasm Metastasis"
      ],
      "interventions": [
        {
          "name": "Rapamycin (sirolimus)",
          "type": "DRUG"
        },
        {
          "name": "Grapefruit Juice",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2006-09",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2014-01-17",
      "last_synced_at": "2026-10-11T12:32:33.904Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00375245"
    },
    {
      "nct_id": "NCT02009449",
      "title": "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Prostate Cancer",
        "Ovarian Cancer",
        "Renal Cell Carcinoma",
        "Colorectal Carcinoma",
        "Pancreatic Carcinoma",
        "Non-small Cell Lung Carcinoma",
        "Solid Tumors",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Pegilodecakin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel or Docetaxel and Carboplatin or Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine/nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine/carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 353,
      "start_date": "2013-11-15",
      "completion_date": "2023-07-22",
      "has_results": true,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-10-11T12:32:33.904Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02009449"
    },
    {
      "nct_id": "NCT05061017",
      "title": "Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NSCLC",
        "Metastatic Colorectal Carcinoma",
        "Refractory Melanoma"
      ],
      "interventions": [
        {
          "name": "Pixatimod",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide (low dose)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Diwakar Davar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2021-12-09",
      "completion_date": "2024-03-18",
      "has_results": true,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-10-11T12:32:33.904Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05061017"
    },
    {
      "nct_id": "NCT03752398",
      "title": "A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma (Excluding Uveal Melanoma)",
        "Cervical Carcinoma",
        "Pancreatic Carcinoma",
        "Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative",
        "Hepatocellular Carcinoma",
        "Urothelial Carcinoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Nasopharyngeal Carcinoma",
        "Renal Cell Carcinoma",
        "Colorectal Carcinoma",
        "Endometrial Carcinoma",
        "Non-small Cell Lung Carcinoma",
        "Small Cell Lung Cancer",
        "Gastric or Gastroesophageal Junction Adenocarcinoma",
        "Advanced Solid Tumors",
        "Undifferentiated Pleomorphic Sarcoma"
      ],
      "interventions": [
        {
          "name": "XmAb®23104",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Yervoy® (ipilimumab)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 198,
      "start_date": "2019-05-01",
      "completion_date": "2024-02-15",
      "has_results": false,
      "last_update_posted_date": "2024-07-05",
      "last_synced_at": "2026-10-11T12:32:33.904Z",
      "location_count": 18,
      "location_summary": "San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03752398"
    },
    {
      "nct_id": "NCT03239145",
      "title": "Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Trebananib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2018-05-01",
      "completion_date": "2024-12-13",
      "has_results": true,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-10-11T12:32:33.904Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03239145"
    }
  ]
}